[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 46 of about 46
1. Hines-Thomas MR, Howard SC, Hudson MM, Krasin MJ, Kaste SC, Shulkin BL, Metzger ML: Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma. Haematologica; 2010 Oct;95(10):1691-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma.
  • BACKGROUND: Bone marrow biopsy is considered essential for the staging and risk-adapted treatment of Hodgkin's lymphoma with unfavorable risk features.
  • We reviewed the cases of pediatric Hodgkin's lymphoma in our institution to determine the impact of bone marrow involvement on treatment, relapse, and survival.
  • DESIGN AND METHODS: We reviewed the clinical characteristics and outcome of 383 patients treated for Hodgkin's lymphoma at St. Jude Children's Research Hospital between August 1990 and August 2008.
  • Bone marrow findings changed the disease stage in only seven patients (3.1%): from IB to IVB (n=1), from IIA (with bulky disease) to IVA (n=1), from IIB to IVB (n=1), and from IIIB to IVB (n=4).
  • One patient's risk assignment changed from intermediate to unfavorable risk without his chemotherapy being altered.
  • No statistically significant difference was observed between patients with stage IV Hodgkin's lymphoma who did (n=21) and did not (n=61) have bone marrow involvement in 5-year relapse-free survival (89.6± 7% versus 73.9±6.1%; P=0.25) or 5-year overall survival (95.2±8.2% versus 87.3±4.9%; P=0.82).
  • CONCLUSIONS: Although bone marrow involvement changed the stage in 3.1% of pediatric Hodgkin's lymphoma patients, it did not change risk-adapted treatment or prognosis.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2002 Nov;119(2):408-11 [12406078.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):630-7 [11821442.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):150-6 [15175959.001]
  • [Cites] N Engl J Med. 1968 May 23;278(21):1179 [5646722.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1733-6 [5121677.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Br J Haematol. 1982 Jul;51(3):345-60 [7104222.001]
  • [Cites] Eur J Haematol. 1987 Jul;39(1):66-70 [3653373.001]
  • [Cites] Eur J Haematol. 1988 Oct;41(4):359-67 [3197822.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):1971-80 [1700080.001]
  • [Cites] Chest. 1991 Mar;99(3):784-5 [1995250.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1591-8 [1714950.001]
  • [Cites] Acta Oncol. 1992;31(1):41-2 [1586503.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):100-8 [8418221.001]
  • [Cites] Haematologica. 1994 May-Jun;79(3):241-55 [7926973.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):403-9 [7844601.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):171-6 [9250802.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2769-79 [9256118.001]
  • [Cites] Med Pediatr Oncol. 1998 Mar;30(3):175-7 [9434827.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):603-9 [9469348.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):897-906 [9508171.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1166-78 [10091803.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4541-50 [15542805.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1875-80 [15536150.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):198-202 [16136581.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jun;28(6):362-8 [16794504.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):256-64 [17154164.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2008 Mar;52(1):9-16 [18235420.001]
  • [Cites] Neoplasma. 2008;55(2):96-100 [18237246.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):765-8 [17763463.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):820-6 [18422997.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3081-7 [12118021.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3765-71 [12228196.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1209-18 [11728679.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):441-4 [12406083.001]
  • (PMID = 20494933.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA-21765
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2948094
  •  go-up   go-down


2. Morais A, Barros MH, Hassan R, Morais VL, Muniz MT: Number of involved anatomic areas as a risk predictor in pediatric Hodgkin's lymphoma: a retrospective study. J Pediatr (Rio J); 2009 May-Jun;85(3):236-42
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of involved anatomic areas as a risk predictor in pediatric Hodgkin's lymphoma: a retrospective study.
  • OBJECTIVES: To determine if the number of involved anatomic areas can modify the standard risk groups in pediatric Hodgkin's lymphoma, identifying children who would benefit from a reduction in treatment intensity.
  • METHODS: Retrospective study evaluating age, sex, histology, Ann-Arbor stage, presence of B symptoms, number of involved anatomic areas, risk grouping (favorable vs. unfavorable), and laboratory exams.
  • All patients received doxorubicin-containing chemotherapy.
  • Advanced stage and > or = four involved anatomic areas had negative impact on event-free survival, while only the number of involved anatomic areas retained statistical significance when using Cox analysis (hazard ratio = 6.4, 95%CI = 1.08-38.33; p = 0.04).
  • CONCLUSIONS: If re-stratification had been applied, a considerable number of children would have received less intensive treatment and, consequently, could have had lower chances of late effects.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Endocrine System Diseases / prevention & control. Heart Diseases / prevention & control. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Epidemiologic Methods. Female. Humans. Male. Prognosis. Risk Factors. Sex Factors. Treatment Outcome


3. Morsi A, Abd El-Ghani Ael-G, El-Shafiey M, Fawzy M, Ismail H, Monir M: Clinico-pathological features and outcome of management of pediatric gastrointestinal lymphoma. J Egypt Natl Canc Inst; 2005 Dec;17(4):251-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathological features and outcome of management of pediatric gastrointestinal lymphoma.
  • PURPOSE: The purpose of this study is to evaluate pediatric GIT lymphomas as regards clinico-pathological features, controversies in surgical treatment, role of chemotherapy and the prognostic features.
  • PATIENTS AND METHODS: This study included forty three patients with pediatric GIT Non-Hodgkin's lymphoma collected over 7 years at the NCI Cairo University between January 1997 and December 2003.
  • The data of every patient included: Age, sex, presenting symptoms and signs, preoperative investigations, extent of the disease at diagnosis and the type of resection performed, histopathological examination, details of chemotherapy and state at follow up.
  • Overall and disease free survival were calculated and correlated with all parameters.
  • Burkitt's lymphoma was the commonest histological type (n=24).
  • The majority were stage IIE and IIIE (22 and 17 respectively).
  • All patients received a sort of systemic chemotherapy.
  • The only parameters that had significantly affected the overall survival were localized disease, complete resection, earlier stage and response to chemotherapy with p values, (0.005, 0.001, 0.005 and <0.001 respectively).
  • As regards the disease free survival the only significant factor was localized disease (p=0.035).
  • CONCLUSION: The extent of disease at presentation is the most important prognostic factor in pediatric GIT lymphoma.
  • Surgery still plays an important role such as complete resection in localized disease, management of complicated disease and diagnostic biopsy.
  • Chemotherapy represents a cornerstone in the treatment and offers an excellent chance for long term, disease free survival.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Combined Modality Therapy. Digestive System Surgical Procedures. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102814.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


Advertisement
4. de Bont ES, Guikema JE, Scherpen F, Meeuwsen T, Kamps WA, Vellenga E, Bos NA: Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma. Cancer Res; 2001 Oct 15;61(20):7654-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma.
  • Autologous peripheral blood stem cell mobilization is increasingly applied in the treatment of hematological malignancies.
  • Despite the frequent clinical use in a setting of residual disease, it is not known whether mobilization of hematopoietic stem cells might facilitate tumor outgrowth in vivo.
  • This hemangioblast, characterized by the expression of CD34 and vascular endothelial growth factor receptor (VEGFR)-2, is released from the bone marrow by mobilization and might be able to result in not only the generation of peripheral blood cells but vasculogenesis due to differentiation of the hemangioblast along the endothelial lineage [in addition to VEGFR-2 expression, angiopoietin-2 (ANG-2) expression can also be found in this stage].
  • A xenotransplant model was established with 10 x 10(6) Daudi cells (non-Hodgkin's lymphoma) s.c. injected in the neck region of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, who were sublethally irradiated with 2 Gy.
  • In the present study, we demonstrate that mobilized human CD34+ hematopoietic cells injected i.v. might facilitate the outgrowth of tumors in the setting of minimal residual disease.
  • This study questions the safety of leukapheresis in patients with (residual) tumor and has important implications for further development of intensive chemotherapy protocols with autologous stem cell rescue.
  • [MeSH-major] Antigens, CD34 / biosynthesis. Hematopoietic Stem Cell Mobilization / adverse effects. Lymphoma, Non-Hodgkin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11606408.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Antigens, CD34; 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Receptors, Growth Factor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


5. Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D: Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol; 2010 Aug 10;28(23):3680-6
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
  • PURPOSE: Vincristine, etoposide, prednisone, and doxorubicin (OEPA)-cyclophosphamide, vincristine, prednisone, and dacarbazine (COPDAC) is derived from standard vincristine, procarbazine, prednisone, and doxorubicin (OPPA)-cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) chemotherapy by replacing procarbazine with etoposide and dacarbazine for a potentially less gonadotoxic regimen for boys with Hodgkin's lymphoma (HL).
  • PATIENTS AND METHODS: Five hundred seventy-three pediatric patients with classical HL were enrolled onto the German Society of Pediatric Oncology and Hematology-Hodgkin's Disease (GPOH-HD) -2002 study between November 2002 and December 2005.
  • Treatment group (TG) -2 (intermediate stages) and TG-3 (advanced stages) patients received further two or four cycles COPP (girls) or COPDAC (boys), respectively.
  • After chemotherapy all patients received involved-field irradiation with 19.8 Gy, except for patients with early-stage disease (TG-1) in complete remission.
  • The median observation time was 58.6 months.
  • Overall survival and event-free survival (EFS) rates (+/- SE) at 5 years were 97.4% +/- 0.7% and 89.0% +/- 1.4%, respectively.
  • EFS of patients without irradiation (93.2% +/- 3.3%) was similar to that of irradiated patients (91.7% +/- 2.5%), confirming results of the previous GPOH-HD-95 study.
  • OPPA-COPP and OEPA-COPDAC seem to be exchangeable regimens in intermediate- and advanced-stage classical HL in pediatric patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Dacarbazine / administration & dosage. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / therapeutic use. Female. Humans. Male. Prednisone / therapeutic use. Procarbazine / administration & dosage. Procarbazine / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; AOPE protocol; OPPA protocol
  •  go-up   go-down


6. Gokhale CD, Udipi SA, Ambaye RY, Pai SK, Advani SH: Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma. J Am Coll Nutr; 2007 Feb;26(1):49-56
Hazardous Substances Data Bank. ZINC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  • OBJECTIVE: To assess serum albumin, total cholesterol, retinol, zinc and hemoglobin in children who had completed treatment for acute lymphoblastic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL).
  • Comparisons were made to stage of treatment (maintenance 6 with post-therapy), type of treatment (chemotherapy and radiation with only chemotherapy) and type of malignancy (ALL with NHL).
  • RESULTS: Only serum albumin in patients included at Maintenance(6) was significantly higher (t = 2.31, p = 0.05) than post-therapy patients.
  • No significant difference in serum values was observed by type of treatment.
  • CONCLUSION: The results of the present study indicate that cancer and its treatment did not have any long-lasting effect on serum albumin, total cholesterol, retinol, zinc and hemoglobin.
  • A higher percentage of patients with low serum retinol levels may also be attributed to the possibility of urinary losses of retinol that occur during episodes of infection while on immunosuppressive anti-cancer drug therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / blood. Nutritional Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Trace Elements / blood. Vitamin A / blood. Vitamins / blood


7. van Grotel M, Lam KH, de Man R, Beishuizen A, Pieters R, van den Heuvel-Eibrink MM: High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leuk Lymphoma; 2006 Aug;47(8):1504-10
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
  • Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare variant of Hodgkin's lymphoma (HL) in children.
  • Since specific immunohistochemical staining has become available, NLPHL can be separated from classical Hodgkin's lymphoma (cHL) more accurately.
  • Scarce information is available about pediatric NLPHL treated with chemotherapy only.
  • Therefore, clinical characteristics, treatment, response and outcome of seven pediatric NLPHL patients, median age 9.2 years (range 7.5 - 14.2 years), diagnosed between 1986 - 2003 among 58 HL patients, uniformly treated in a single center with chemotherapy only, were evaluated.
  • The median follow-up time was 4.2 years (range 2.1 - 10.2 years).
  • NLPHL patients were stage I (n = 5), II (n = 2), whereas cHL, median age 11.4 years (range 3.3 - 15.9 years), were stage I (n = 8), II (n = 17), III (n = 9), IV (n = 1).
  • Upfront treatment of NLPHL patients consisted of six courses of epirubicin, bleomycin, vinblastine and dacarbazine (EBVD) without radiotherapy, whereas cHL patients received six courses of EBVD (n = 14) or 4 - 6 courses of EBVD/MOPP (mitoxin, oncovin, procarbazine, prednison; n = 21).
  • Chemotherapy was used as primary treatment thereby aiming to avoid radiotherapy with potential serious side effects to growing jaws and thyroid.
  • These three were salvaged with second-line chemotherapy without radiation therapy (RT) and are in second CR.
  • One patient relapsing with stage III disease was salvaged by EBVD/MOPP followed by autologous BMT and is also in second CR for 36 months.
  • Moreover, it illustrates that although cure of pediatric NLPHL is feasible with chemotherapy only, high dosages of cytotoxic drugs are necessary as salvage treatment in a relatively high proportion of patients after relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Child. Dacarbazine / administration & dosage. Epirubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Recurrence. Remission Induction / methods. Retrospective Studies. Salvage Therapy / methods. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Aug;47(8):1450-1 [16966251.001]
  • (PMID = 16966260.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


8. Chauhan A, Weiss J, Warrier R: Effective management of pain in pediatric hematology and oncology. Asian Pac J Cancer Prev; 2010;11(2):577-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective management of pain in pediatric hematology and oncology.
  • In the last several decades, there have been major advances in the treatment of pediatric cancers.
  • Early stages of non -Hodgkin's, Hodgkin's and Wilms tumors all have more than 90% long term survival.
  • Bone pain is also a prominent symptom in late stage neuroblastoma, and of course in bone tumors.
  • Pain due to disease burden responds dramatically to chemotherapy and the uninitiated are often surprised by the sudden increase in activity and playfulness of children undergoing induction chemotherapy.
  • [MeSH-major] Hodgkin Disease / complications. Kidney Neoplasms / complications. Lymphoma, Non-Hodgkin / complications. Pain / drug therapy. Pain / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Wilms Tumor / complications

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20843157.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


9. Kelly KM, Hutchinson RJ, Sposto R, Weiner MA, Lones MA, Perkins SL, Massey V, Children's Oncology Group: Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol; 2002;13 Suppl 1:107-11
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.
  • BACKGROUND: Treatment strategies involving dose intensification have recently demonstrated improvements in cure compared with older trials.
  • However, dose-intensive therapy is associated with increased acute and long-term toxicities, particularly in pediatric patients.
  • The Children's Cancer Group initiated this pilot study to assess the feasibility and toxicity of a moderate dose-intensive regimen, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone), in children and adolescents with advanced-stage Hodgkin's lymphoma (HL).
  • PATIENTS AND METHODS: Children with stage IIB or IIIB with bulk disease, or stage IV were eligible.
  • The rapidity of response, defined as >70% reduction in disease burden, was assessed after two and four cycles.
  • Rapid responders then received consolidation therapy as per gender-specific guidelines to reduce the risk of gender-specific long-term toxicities of therapy, i.e. females received four cycles of COPP/ABV (cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin and vinblastine) without radiation therapy and males received two cycles of ABVD (doxurubicin, bleomycin, vinblastine and dacarbazine) with involved field radiation therapy (IFRT).
  • Typhlitis developed in four patients; three recovered and completed dose-modified chemotherapy, while one died of sepsis associated with grade 4 neutropenia.
  • There are no disease progressions or secondary malignancies to date.
  • CONCLUSIONS: BEACOPP chemotherapy is feasible and generally well tolerated in children with advanced-stage HL.
  • The absence of reported progressive disease and only one relapse to date is encouraging.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078889.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


10. Shukla NN, Trippett TM: Non-Hodgkin's lymphoma in children and adolescents. Curr Oncol Rep; 2006 Sep;8(5):387-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in children and adolescents.
  • Lymphoma is the third most common cancer in children and adolescents.
  • Non-Hodgkin's lymphomas comprise a heterogeneous group of tumors with distinct pathologic and clinical characteristics.
  • With the use of intensive multiagent chemotherapy, non-Hodgkin's lymphomas are now among the most successfully treated cancers in the pediatric population.
  • Future goals of therapy include reduction of treatment duration for early-stage patients and identification of novel targets and therapeutics for advanced-stage patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1992 Feb;27(2):230-5 [1564623.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):92-9 [2642543.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):383-9 [10667591.001]
  • [Cites] Mol Imaging Biol. 2004 Nov-Dec;6(6):411-6 [15564152.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):186-93 [2915234.001]
  • [Cites] Blood. 1996 Jan 15;87(2):423-38 [8555463.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):31-8 [15605288.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):697-704 [11157020.001]
  • [Cites] Med Pediatr Oncol. 1975;1(3):235-63 [1232532.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Cancer Surv. 1997;30:59-75 [9547986.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1155-65 [12192560.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):496-506 [15080301.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):95-100 [9709310.001]
  • [Cites] J Biol Chem. 1992 Apr 25;267(12):8565-70 [1339455.001]
  • [Cites] J Pediatr. 1994 Dec;125(6 Pt 1):876-85 [7996359.001]
  • [Cites] Leukemia. 2005 Jan;19(1):34-8 [15510203.001]
  • [Cites] Br J Haematol. 2004 May;125(3):414-5 [15086431.001]
  • [Cites] Exp Hematol. 2003 Apr;31(4):309-15 [12691918.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):753-69 [15929129.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Med Pediatr Oncol. 2000 Jul;35(1):20-7 [10881003.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1729-35 [9586885.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3845-53 [11078498.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2485-501 [16243519.001]
  • [Cites] Ann Nucl Med. 2002 Jul;16(5):337-45 [12230093.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3591-8 [9808552.001]
  • [Cites] JAMA. 2000 Jul 12;284(2):205-9 [10889594.001]
  • [Cites] Leuk Lymphoma. 2005 Oct;46(10):1489-96 [16194895.001]
  • [Cites] Leukemia. 2004 Feb;18(2):238-42 [14628072.001]
  • [Cites] Blood. 2001 May 15;97(10):2998-3003 [11342423.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2293-301 [11981000.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8414-21 [16293872.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4319-27 [11110708.001]
  • [Cites] Am J Hematol. 2003 Jan;72(1):53-63 [12508269.001]
  • [Cites] Br J Haematol. 2001 May;113(2):275-95 [11380391.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):282-96 [9702999.001]
  • [Cites] Curr Opin Genet Dev. 1994 Feb;4(1):102-8 [8193530.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2133-40 [16211546.001]
  • [Cites] Br J Haematol. 1999 Mar;104(4):680-8 [10192426.001]
  • (PMID = 16901400.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


11. Gore L, Trippett TM: Emerging non-transplant-based strategies in treating pediatric non-Hodgkin's lymphoma. Curr Hematol Malig Rep; 2010 Oct;5(4):177-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging non-transplant-based strategies in treating pediatric non-Hodgkin's lymphoma.
  • The non-Hodgkin's lymphomas comprise a heterogeneous group of tumors, with distinct clinical and pathologic features.
  • Although intensive multi-agent chemotherapy has made non-Hodgkin's lymphoma one of the most curable malignancies in children and young adults, there is room for improvement in treatment, particularly for those with advanced-stage disease and those who relapse after conventional therapy.
  • New approaches are now attempting to reduce the burden of treatment, to focus on novel and more specific biologic targets, and to improve outcomes for patients with advanced-stage disease while reducing the potential for late effects.
  • A comprehensive review of all potential agents is beyond the scope of this review, which will focus on some of the newer strategies for treating non-Hodgkin's lymphoma that are coming into clinical use today.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Burkitt Lymphoma / pathology. Burkitt Lymphoma / therapy. Child. Cysteine Proteinase Inhibitors / therapeutic use. Histone Deacetylase Inhibitors / therapeutic use. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Kinase Inhibitors / therapeutic use. Purine-Nucleoside Phosphorylase / antagonists & inhibitors. TNF-Related Apoptosis-Inducing Ligand / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1992 Feb;27(2):230-5 [1564623.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):92-9 [2642543.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):383-9 [10667591.001]
  • [Cites] Mol Imaging Biol. 2004 Nov-Dec;6(6):411-6 [15564152.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] Blood. 1996 Jan 15;87(2):423-38 [8555463.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):31-8 [15605288.001]
  • [Cites] Med Pediatr Oncol. 1975;1(3):235-63 [1232532.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Cancer Surv. 1997;30:59-75 [9547986.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Cancer Invest. 2004;22(2):304-11 [15199612.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1155-65 [12192560.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):496-506 [15080301.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):95-100 [9709310.001]
  • [Cites] J Pediatr. 1994 Dec;125(6 Pt 1):876-85 [7996359.001]
  • [Cites] Curr Med Chem. 2006;13(26):3165-89 [17168705.001]
  • [Cites] Br J Haematol. 2004 May;125(3):414-5 [15086431.001]
  • [Cites] Exp Hematol. 2003 Apr;31(4):309-15 [12691918.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):307-10 [19856388.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):753-69 [15929129.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Med Pediatr Oncol. 2000 Jul;35(1):20-7 [10881003.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1729-35 [9586885.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3535-40 [11325813.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3845-53 [11078498.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2485-501 [16243519.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41 [19875969.001]
  • [Cites] Ann Nucl Med. 2002 Jul;16(5):337-45 [12230093.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3591-8 [9808552.001]
  • [Cites] JAMA. 2000 Jul 12;284(2):205-9 [10889594.001]
  • [Cites] Leuk Lymphoma. 2005 Oct;46(10):1489-96 [16194895.001]
  • [Cites] Leukemia. 2004 Feb;18(2):238-42 [14628072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4319-27 [11110708.001]
  • [Cites] Am J Hematol. 2003 Jan;72(1):53-63 [12508269.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3371-6 [15161691.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):282-96 [9702999.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2133-40 [16211546.001]
  • (PMID = 20640605.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cysteine Proteinase Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Protein Kinase Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase
  •  go-up   go-down


12. Ali A, Sayed H, Farrag A, El-Sayed M: Risk-based combined-modality therapy of pediatric Hodgkin's lymphoma: a retrospective study. Leuk Res; 2010 Nov;34(11):1447-52
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-based combined-modality therapy of pediatric Hodgkin's lymphoma: a retrospective study.
  • We conducted a retrospective analysis to investigate the clinical outcome of combined-modality therapy using multiagent chemotherapy and involved-field radiotherapy in treatment of children with Hodgkin's lymphoma.
  • Fifty eight cases with newly diagnosed Hodgkin's lymphoma were analyzed.
  • High-risk disease (stage IIIB and IV), presence of B symptoms, lymphocyte depletion subtype, bulky disease and late response to chemotherapy were poor prognostic factors.
  • Stage-adapted combined-modality therapy resulted in satisfactory outcome in treatment of pediatric Hodgkin's lymphoma.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Prognosis. Radiotherapy. Retrospective Studies. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20599270.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Attarbaschi A, Mann G, Dworzak M, Trebo M, Mühlegger N, Reiter A, Horcher E, Gadner H, Austrian Cooperative Study Group: The role of surgery in the treatment of pediatric B-cell non-Hodgkin's lymphoma. J Pediatr Surg; 2002 Oct;37(10):1470-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surgery in the treatment of pediatric B-cell non-Hodgkin's lymphoma.
  • BACKGROUND: Within the last 20 years, the role of surgery in the management of pediatric B-cell non-Hodgkin's lymphoma (B-NHL) has changed substantially.
  • Along with the assignment of risk-adjusted therapy and specific treatment protocols, surgical procedures have been restricted to defined situations including abdominal emergencies, diagnostic biopsy, total tumor extirpation and second-look operations.
  • Furthermore, the prognostic significance of the stage of disease for the patients analyzed was evaluated.
  • RESULTS: Therapy results showed that the extent of resection did not have a significant influence on EFS and that stage of disease was of prognostic relevance only for patients with head and neck tumors.
  • CONCLUSIONS: Because tumor resectability is determined by the stage of disease, which is the superimposed predictor of prognosis, the influence of the extent of resection on EFS cannot be interpreted independently.
  • Nevertheless, the following conclusions can be drawn: in patients with proven localized disease, total resections should be attempted, if not mutilating, to avoid intensified chemotherapy.
  • [MeSH-major] Abdominal Neoplasms / surgery. Head and Neck Neoplasms / surgery. Lymphoma, B-Cell / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Reoperation. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12378457.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Forns M, Javier G, Estella J, Fernández-Delgado R, Gallego S, García-Miguel P, Indiano JM, Navajas A, Pardo N, en representación del grupo SHOP de las Sociedades Españolas de Hematología (SEHP) y Oncología Pediátricas (SEOP): [Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin's lymphoma]. Med Clin (Barc); 2007 May 5;128(17):641-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin's lymphoma].
  • BACKGROUND AND OBJECTIVE: After the good results obtained by the Société Française d'Oncologie Pédiatrique (SFOP) regarding the pediatric B-type non-Hodgkin's (Burkitt and large B-cell) lymphoma and L3 leukemia, the Sociedad Española de Hematología y Oncología Pediátricas (SHOP) decided to use the same treatment protocol.
  • PATIENTS AND METHOD: Pediatric patients diagnosed with B-type non-Hodgkin's lymphoma without a previous history of malignant diseases were eligible for this study.
  • They were classified in 3 groups of risk: group A (resected stage I and abdominal stage II), group B (not eligible for groups A or C), and group C (with central nervous system involvement and L3 leukemia).
  • All received treatment according to the SFOP's LMB89 protocol.
  • CONCLUSIONS: The results confirm the good efficiency of the LMB89 protocol for treating B-cell lymphoma and L3 leukemia, despite having diminished the treatment intensity in the less risk groups.
  • In addition, no differences were evidenced between Burkitt and large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Hydrocortisone / therapeutic use. Infant. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Prednisone / therapeutic use. Prospective Studies. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537360.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Spain
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; LMB89 protocol
  •  go-up   go-down


15. Seidemann K, Henze G, Beck JD, Sauerbrey A, Kühl J, Mann G, Reiter A: Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol; 2000;11 Suppl 1:141-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials.
  • BACKGROUND: Lymphoma and leukemia are the commonest malignant diseases in patients with chromosomal breakage syndromes and immunodeficiency (Ataxia teleangiectasia (AT) and Nijmegen breakage syndrome (NBS)).
  • With improved management of infections, malignant disease is more frequently diagnosed and has become one of the commonest causes of death in pediatric AT and NBS.
  • PATIENTS AND METHODS: In three consecutive multicenter therapy trials for pediatric non-Hodgkin's lymphoma (NHL) (NHL-BFM), 1569 patients with newly diagnosed NHL have been registered between 1986 and 1997.
  • NHL-entities differed from non-AT/NBS-patients: diffuse large B-cell lymphomas, n = 7 (78%); ALCL, n = 1; lymphoblastic T-cell lymphoma, n = 1.
  • All patients received polychemotherapy according to tumor-entity and stage, none received radiation.
  • CONCLUSIONS: Patients with AT and NBS suffer from rare entities of pediatric NHL.
  • Curative treatment is possible and should be attempted.
  • Intensity of therapy should be adjusted to individual risk factors and tolerance.

  • MedlinePlus Health Information. consumer health - Ataxia Telangiectasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707797.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Berrak SG, Türkkan E, Canpolat C, Iskit S, Dağli T, Abacioğlu U: Partial intestinal obstruction due to childhood refractory hon-Hodgkin's lymphoma, successfully treated with taxol. Eur J Pediatr Surg; 2003 Aug;13(4):276-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial intestinal obstruction due to childhood refractory hon-Hodgkin's lymphoma, successfully treated with taxol.
  • In this report, we present a six-year-old male patient with partial intestinal obstruction due to refractory Non-Hodgkin's lymphoma (NHL) whose partial obstruction was successfully treated with Taxol(R) without any surgical intervention.
  • Following an unsuccessful treatment attempt to treat his high-grade (stage 3) B-cell lymphoma with standard and second-line chemotherapy regimens he was started on radiotherapy and third line chemotherapy during which he was admitted with partial obstructive ileus as a result of tumor progression.
  • Treatment was continued with Taxol(R) and resulted in total cure of the ileus with reduction of palpable tumor mass over 24 h without necessitating any surgery.
  • After the next course, the patient developed severe thrombocytopenia that unfortunately did not resolve before the patient died as a result of further tumor growth and dissemination.
  • Although there are studies that report response to Taxol(R) treatment in adult patients with refractory NHL, our review of the literature failed to demonstrate any report about the effectiveness of Taxol(R) in childhood NHL.
  • Studies on larger number of patients are needed to make a definitive conclusion about the value of Taxol(R) in refractory childhood NHL.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Ileal Neoplasms / drug therapy. Intestinal Obstruction / drug therapy. Lymphoma, B-Cell / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13680500.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Laver JH, Mahmoud H, Pick TE, Hutchison RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma; 2002 Jan;43(1):105-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
  • PURPOSE: The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage.
  • Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas.
  • PATIENTS AND METHODS: One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991.
  • In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2.
  • Radiation was administered to bulky disease if progression or no response were observed after induction therapy.
  • Planned duration of therapy was 12 months.
  • While there was no statistically significant difference between the two treatment arms (p = 0.28), we can only say that we are 95% confident that the difference in 5-year EFS falls in the wide range from 28% in favor of APO to 8% favoring ACOP+.
  • Ten patients received radiation therapy to achieve remission.
  • CONCLUSION: The efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS.
  • Furthermore, the majority of the patients (92%) did not require any radiation therapy to bulky disease indicating that the chemotherapy regimens are quite efficient for achievement of complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Child. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Prednisone / administration & dosage. Prospective Studies. Recurrence. Remission Induction / methods. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908712.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03161; United States / NCI NIH HHS / CA / CA05587; United States / NCI NIH HHS / CA / CA11233; United States / NCI NIH HHS / CA / CA15089; United States / NCI NIH HHS / CA / CA20549; United States / NCI NIH HHS / CA / CA25408; United States / NCI NIH HHS / CA / CA28383; United States / NCI NIH HHS / CA / CA28476; United States / NCI NIH HHS / CA / CA29139; United States / NCI NIH HHS / CA / CA30696; United States / NCI NIH HHS / CA / CA32053; United States / NCI NIH HHS / CA / CA33603; United States / NCI NIH HHS / CA / CA35587; United States / NCI NIH HHS / CA / CA69177; United States / NCI NIH HHS / CA / CA69428
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ACOP protocol 2
  •  go-up   go-down


18. Delarue A, Bergeron C, Mechinaud-Lacroix F, Coze C, Raphael M, Patte C, pour le "Comité Lymphome" de la SFCE: [Pediatric non-Hodgkin's lymphoma: primary surgical management of patients presenting with abdominal symptoms. Recommendations of the Lymphoma Committee of the French Society to Combat Pediatric Cancers (SFCE)]. J Chir (Paris); 2008 Sep-Oct;145(5):454-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pediatric non-Hodgkin's lymphoma: primary surgical management of patients presenting with abdominal symptoms. Recommendations of the Lymphoma Committee of the French Society to Combat Pediatric Cancers (SFCE)].
  • Over the past two decades, dramatic improvements in the treatment of children with Non-Hodgkin's Lymphoma have led to cure rates close to 90%, even in advanced-stage disease.
  • The SFCE Lymphoma Committee's guidelines for optimal management include:.
  • 1) The diagnosis of lymphoma should be systematically evoked whenever the clinical context is not consistent with idiopathic intussusception, particularly in children over the age of 3 or when clinical and/or ultrasound findings are not typical;.
  • 4) In all cases, adequate tissue should be obtained and sent to the pathology department in appropriate media Analysis of tumor material may require, in addition to histology and cytology, immunophenotyping, cytogenetics, and molecular biology studies in order to arrive at an accurate diagnosis and prognosis and to guide treatment choices.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / surgery. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery. Practice Guidelines as Topic
  • [MeSH-minor] Abdominal Pain / etiology. Chemotherapy, Adjuvant. Child. Evidence-Based Medicine. France. Humans. Societies, Medical. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106866.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 38
  •  go-up   go-down


19. Dalle JH, Mechinaud F, Michon J, Gentet JC, de Lumley L, Rubie H, Schmitt C, Patte C: Testicular disease in childhood B-cell non-Hodgkin's lymphoma: the French Society of Pediatric Oncology experience. J Clin Oncol; 2001 May 01;19(9):2397-403
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular disease in childhood B-cell non-Hodgkin's lymphoma: the French Society of Pediatric Oncology experience.
  • PURPOSE: To investigate whether testicular disease in childhood B-cell lymphoma should continue to be considered a sanctuary site, as it is with other lymphoid malignancies such as acute lymphoblastic leukemia.
  • PATIENTS AND METHODS: Seven hundred forty-two children with B-cell non-Hodgkin's lymphoma were included in the LMB protocols of the French Society of Pediatric Oncology from February 1981 to May 1994.
  • We describe the clinical presentation and outcome of these 30 patients, who were treated without local radiation therapy.
  • The median patient age was 8.5 years (range, 2 to 14 years), and their cancers were stage III (18 patients), stage IV (five patients), and B-cell acute lymphoblastic leukemia (seven patients).
  • Twenty-six patients are alive without progressive disease (median follow-up, 6.5 years).
  • CONCLUSION: Testicular disease does not seem to confer a poor prognosis, and it is curable with intensive combination chemotherapy alone.
  • Local treatment (surgery or radiation) is avoidable; therefore, gonadal function can be preserved.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11331318.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Weitzman S, Suryanarayan K, Weinstein HJ: Pediatric non-Hodgkin's lymphoma: clinical and biologic prognostic factors and risk allocation. Curr Oncol Rep; 2002 Mar;4(2):107-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric non-Hodgkin's lymphoma: clinical and biologic prognostic factors and risk allocation.
  • The use of effective combination chemotherapy for all stages and subtypes of non-Hodgkin"s lymphoma (NHL) in children has resulted in a striking improvement in cure rates.
  • Event-free survival now ranges from 70% to 90%, depending on the stage of disease and the NHL subtype.
  • Risk-adapted therapy has resulted in a dramatic improvement in outcome for high-risk patients, at the cost of significantly increased short-term toxicity, and a reduction of therapy and toxicity for the lower-risk patient, while maintaining the excellent cure rate.
  • The specific treatment protocol is the single most important factor predicting outcome today.
  • Traditional prognostic factors such as stage and tumor burden are useful in selecting the intensity and length of therapy, rather than as a major indicator of likelihood of survival.
  • Some promising avenues for study appear to be the presence or absence of adhesion molecules and of aberrant proteins that are specific to subtypes of lymphomas, such as soluble CD30 and anaplastic lymphoma kinase (ALK), the molecular classification of lymphomas on the basis of gene expression, and the evaluation of biologic markers for measuring early response to therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Protocols. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Child, Preschool. Disease-Free Survival. Humans. Neoplasm Staging. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Aug 15;96(4):1605-7 [10942417.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1900-10 [10706853.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2023-32 [7636544.001]
  • [Cites] Blood. 1995 May 15;85(10):2885-99 [7537983.001]
  • [Cites] Blood. 1997 Jul 1;90(1):244-51 [9207459.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1532-7 [9552063.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3509-15 [10552961.001]
  • [Cites] Pathologe. 2000 Mar;21(2):124-36 [10840818.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1043-52 [10632924.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Med Pediatr Oncol. 2001 Aug;37(2):97-102 [11496346.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Pediatr Int. 1999 Dec;41(6):637-40 [10618883.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3713-20 [11389007.001]
  • [Cites] Semin Diagn Pathol. 1995 Nov;12(4):303-13 [8578025.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3591-8 [9808552.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] J Pathol. 1997 Jun;182(2):145-50 [9274523.001]
  • [Cites] Cancer. 1979 Dec;44(6):2218-35 [389411.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):282-96 [9702999.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:43-7 [9187428.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1368-76 [7751881.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 1996 Nov 15;88(10):3919-25 [8916958.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • (PMID = 11822982.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


21. Glotzbecker MP, Kersun LS, Choi JK, Wills BP, Schaffer AA, Dormans JP: Primary non-Hodgkin's lymphoma of bone in children. J Bone Joint Surg Am; 2006 Mar;88(3):583-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of bone in children.
  • BACKGROUND: Primary non-Hodgkin's lymphoma of bone, often more simply referred to as primary lymphoma of bone, is a rare subset of non-Hodgkin's lymphoma in children.
  • There are only a few small series of primary lymphoma of bone in children with long-term follow-up, and none have appeared in the orthopaedic literature.
  • METHODS: A review of our institution's Pediatric Tumor Registry identified fifteen cases of primary lymphoma of bone among 306 cases of diagnosed non-Hodgkin's lymphoma between 1970 and 2003.
  • Retrospective evaluation included collection of demographic, clinical, radiographic, treatment, and follow-up data.
  • Five patients died: three of disease progression, one of treatment-related complications, and one of an unrelated cause.
  • The mean time from diagnosis to death was 2.1 years.
  • Nine patients received chemotherapy only, whereas six patients received a combination of chemotherapy and radiation therapy.
  • In the summary analysis of cases collected from the literature, advanced stage, young age, non-large-cell histology, and multiple-bone involvement were predictive of poor survival (p < 0.05).
  • CONCLUSIONS: On the basis of the present series and a comprehensive review of similar series in the literature involving patients with primary lymphoma of bone, it appears that younger age, advanced-stage disease, multiple-bone involvement, and non-large-cell histology are associated with decreased survival as compared with older age, localized disease, single-bone involvement, and large-cell histology, respectively.
  • [MeSH-major] Bone Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510826.001).
  • [ISSN] 0021-9355
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kutluk T, Varan A, Akyüz C, Büyükpamukçu M: Clinical characteristics and treatment results of LMB/LMT regimen in children with non-Hodgkin's lymphoma. Cancer Invest; 2002;20(5-6):626-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and treatment results of LMB/LMT regimen in children with non-Hodgkin's lymphoma.
  • Ninety-seven patients with newly diagnosed, untreated non-Hodgkin's lymphoma, between April 1994 and December 1997, were included in this study.
  • Modified lymphoma malign B (LMB) and lymphoma malign T (LMT) regimens were used for treatment of B- and T-cell disease, respectively.
  • Ten (10.3%), 68 (70.1%), and 19 (19.6%) patients had stage II, III, and IV disease, respectively.
  • Two-year overall survival rates were 90, 66.1, and 50.8% for patients with stage II, III, and IV disease, respectively.
  • Poor response at the end of cytoreductive treatment and age younger than 4 years were poor prognostic factors.
  • Pediatric lymphomas could be treated safely and effectively by LMB and LMT regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Developing Countries. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Female. Humans. Infant. Male. Retrospective Studies. Survival Analysis. Treatment Outcome. Turkey

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12197217.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Chow LM, Nathan PC, Hodgson DC, Jenkin D, Weitzman S, Grant RM, Manson D, Bross A, Doyle JJ, Danjoux C, Greenberg ML: Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol; 2006 Dec 20;24(36):5735-41
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
  • PURPOSE: Reduced-intensity protocols for pediatric Hodgkin's lymphoma are aimed at preserving excellent relapse-free survival while decreasing the incidence of late effects.
  • PATIENTS AND METHODS: We retrospectively reviewed the outcome of 123 children treated consecutively for Hodgkin's lymphoma at a single institution.
  • Patients with stages I-IIIB disease received three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)/ doxorubicin, bleomycin, and vinblastine (ABV) followed by 15 Gy of extended-field irradiation, while those with stage IV disease were treated with six to eight cycles of MOPP/ABV chemotherapy with or without radiotherapy.
  • RESULTS: At a median follow-up of 8.5 years (range, 1.4 to 15.5 years), the estimated 10-year overall survival and event-free survival are 94% (SE, 2.2%) and 88% (SE, 3.1%) respectively.
  • There have been 12 treatment failures and six disease-related deaths.
  • A very large mediastinal mass ( 50% of the maximal thoracic diameter) was associated with a 10-year event-free survival of 50% (SE, 14%) compared with 91% (SE, 4.0%) for smaller masses (P < .001).
  • CONCLUSION: MOPP/ABV and low-dose, extended-field radiotherapy is an effective treatment for pediatric Hodgkin's lymphoma.
  • With median follow-up of 8.5 years, late cardiopulmonary effects and secondary malignancies from this treatment regimen are infrequent.
  • Continued longitudinal observations, particularly for breast cancer in female patients and gonadotoxicity, will determine whether the goal of decreasing treatment-related complications while maintaining excellent survival has been achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Heart / drug effects. Humans. Hypothyroidism / etiology. Infant. Lung / drug effects. Male. Mechlorethamine / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; MOPP-ABV protocol
  •  go-up   go-down


24. Howman-Giles R, London K, McCowage G, Graf N, Harvey J: Pulmonary inflammatory myofibroblastic tumor after Hodgkin's lymphoma and application of PET imaging. Pediatr Surg Int; 2008 Aug;24(8):947-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary inflammatory myofibroblastic tumor after Hodgkin's lymphoma and application of PET imaging.
  • This case report is of a 16-year-old male who had Hodgkin's disease (stage IVA) and who after chemotherapy and radiotherapy developed IMT, 16 months post completion of therapy.
  • The IMT was in the lung in an area which was previously involved with HD and had undergone radiotherapy.
  • [MeSH-major] Fibrosarcoma / diagnosis. Hodgkin Disease / complications. Lung Neoplasms / diagnosis. Neoplasms, Muscle Tissue / diagnosis. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Pneumonectomy. Tomography, X-Ray Computed


25. Laver JH, Mahmoud H, Pick TE, Hutchinson RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ, Pediatric Oncology Group: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma; 2001 Jul;42(3):399-405
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
  • The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage.
  • Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas.
  • One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991.
  • In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2.
  • Radiation was administered to bulky disease if progression or no response were observed after induction therapy.
  • Planned duration of therapy was 12 months.
  • While there was no statistically significant difference between the two treatment arms (p = 0.28), we can only say that we are 95% confident that the difference in 5-year EFS falls in the wide range from 28% in favor of APO to 8% favoring ACOP+.
  • Ten patients received radiation therapy to achieve.
  • In conclusion the efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS.
  • Furthermore, the majority of the patients (92%) did not require any radiation therapy to bulky disease indicating that the chemotherapy regimens are quite efficient for achievement of complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Antigens, CD / analysis. Child. Continental Population Groups. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Immunohistochemistry. Neoplasm Metastasis. Prednisolone / administration & dosage. Prednisone / administration & dosage. Remission Induction. Time Factors. United States. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699405.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; VAP-cyclo protocol; VPD protocol
  •  go-up   go-down


26. Bradley MB, Cairo MS: Stem cell transplantation for pediatric lymphoma: past, present and future. Bone Marrow Transplant; 2008 Jan;41(2):149-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell transplantation for pediatric lymphoma: past, present and future.
  • Lymphoma is the third most common cancer in children < or =15 years of age.
  • The prognosis for children with newly diagnosed chemosensitive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) has improved significantly.
  • However, in children with relapsed and refractory NHL, the prognosis is not as promising and the best treatment approach for this poor risk group continues to be a challenge.
  • Between 25 and 30% of patients with advanced stage HD still relapse and in subsets of this group, the outcome is dismal.
  • Aggressive chemotherapy followed by autologous bone marrow transplantation has been used with some improvement in survival.
  • Some centers have investigated allogeneic stem cell transplantation in pediatric patients with recurrent/relapsed lymphoma.
  • There is little consistency in therapeutic approaches and there is no formal recommendation on the best approach for this poor prognostic subgroup.
  • We illustrate the reported pediatric experience of transplantation for lymphoma and discuss how the results from these trials are influencing how we approach the treatment in certain subgroups of pediatric patients with relapsed/refractory lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma / therapy. Neoplasm Recurrence, Local / therapy


27. Won SC, Han JW, Kwon SY, Shin HY, Ahn HS, Hwang TJ, Yang WI, Lyu CJ: Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology. Ann Hematol; 2006 Nov;85(11):787-94
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology.
  • Recent development of stratified chemotherapeutic regimens has rapidly improved the survival rate of non-Hodgkin's lymphoma (NHL) of childhood.
  • We explored the use of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/PBSCT) for children with either refractory or recurrent NHL, and we evaluated various factors influencing outcome of HDC/PBSCT.
  • Sex, stage at diagnosis, histologic subtype (lymphoblastic, Burkitt's, and large-cell lymphoma), LDH level at diagnosis, disease status at transplantation, and preparative regimens for HDC/PBSCT were explored.
  • In regard to the patients, six had Burkitt's lymphoma, 13 had lymphoblastic lymphoma, and 14 had large-cell lymphoma.
  • The EFS for Burkitt's, lymphoblastic, and large-cell lymphoma was 66.7+/-27.2, 50.5+/-14.8, and 82.1+/-11.7%, respectively.
  • In comparison with lymphoblastic and non-lymphoblastic lymphoma, the relative risk for lymphoblastic lymphoma was higher than the others (P = 0.037).
  • EFS between anaplastic large-cell and diffuse large-cell lymphoma was 100 and 55.6+/-24.9%, respectively (P = 0.106).
  • HDC/PBSCT is considered applicable to recurrent or refractory pediatric NHL patients safely and it could replace conventional chemotherapy.
  • In this study, children with CR status at the time of HDC/PBSCT showed higher survival rate.
  • However, refractory or recurrent lymphoblastic lymphoma patients showed dismal results.
  • Therefore, new therapeutic modalities may be needed for this group of NHL patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Korea. Male. Retrospective Studies. Salvage Therapy. Survival. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Hematol. 2007 Apr;86(4):309
  • (PMID = 16932891.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Balwierz W, Moryl-Bujakowska A, Depowska T, Klekawka T, Stanuch H, Matysiak M, Sopyło B, Kołakowska-Mrozowska B, Krenke K, Chybicka A, Raś M, Sońta-Jakimczyk D, Moszant A, Wachowiak J, Kaczmarek-Kanold M, Kowalczyk J, Odój T, Balcerska A, Drozyńska E, Wysocki M, Kołtan A, Krawczuk-Rybak M, Stolarska M: [Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications]. Przegl Lek; 2004;61 Suppl 2:33-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications].
  • Currently over 90% of children with HD can be cured thanks to use of chemotherapy (CT) combined with involved field radiotherapy (IF-RT).
  • From 1971 to 2001, 1062 children and adolescents with HD (stage I to IV) were treated in 10 oncological centers PPLLSG.
  • Year by year the intensity of therapy (CT and RT) was gradually adjusted to the risk-factor groups, and invasive methods of staging were also gradually limited.
  • Supportive care was improved at the same time.
  • Along with the modified therapy protocol, five consecutive periods of time (I: 1971-82; II: 1983-87; IIII: 1988-93; IV: 1994-96; V: 1997-2001) were analyzed.
  • In order to decrease the incidence of late complications, the dose of IF-RT from 45 Gy to 15-30 Gy was reduced in the next periods.
  • In V period in 21 children with stage IA and IIA with favorable prognostic factors, CT alone was used.
  • Intensity of therapy should be tailored to the stage of disease, and to other significant prognostic factors.
  • The current strategy of diagnosing and treatment of HD is aimed at balancing between the highest possible cure rates and risk of late complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Child. Child, Preschool. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Mechlorethamine / administration & dosage. Multicenter Studies as Topic. Poland. Prednisolone / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Recurrence. Remission Induction. Retrospective Studies. Survival Analysis. Time Factors. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15688474.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; B-DOPA protocol; MVPP protocol
  •  go-up   go-down


29. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, Leblanc T, Perel Y, Bertrand Y, Beard C, Edan C, Schmitt C, Plantaz D, Pacquement H, Vannier JP, Lambilliote C, Couillault G, Babin-Boilletot A, Thuret I, Demeocq F, Leverger G, Delsol G, Landman-Parker J, Study of the French Society of Pediatric Oncology: Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology. J Clin Oncol; 2003 Aug 1;21(15):2948-52
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology.
  • PURPOSE: To clarify treatment strategy for lymphocyte-predominant Hodgkin's lymphoma (LPHL), the French Society of Pediatric Oncology initiated a prospective, nonrandomized study in 1988.
  • Patients received either standard treatment for Hodgkin's lymphoma or were not treated beyond initial adenectomy.
  • Twenty-two, two, and three patients had stage I, II, and III disease, respectively.
  • Thirteen patients (stage I, n = 11; stage III, n = 2) received no further treatment after initial surgical adenectomy (SA).
  • Fourteen patients received combined treatment (CT; n = 10), involved-field radiotherapy alone (n = 1), or chemotherapy alone (n = 3).
  • The two groups were comparable for clinical status, treatment, and follow-up.
  • With a median follow-up time of 70 months (range, 32 to 214 months), overall survival to date is 100%, and overall event-free survival (EFS) is 69% +/- 10% (SA, 42% +/- 16%; CT, 90% +/- 8.6%; P <.04).
  • Patients with residual mass after initial surgery (n = 15) had worse EFS if they did not receive complementary treatment (P <.05).
  • no further therapy is a valid therapeutic approach in LPHL patient in CR after initial lymph node resection, and (2).
  • complementary treatment diminishes relapse frequency but has no impact on survival.
  • [MeSH-major] Hodgkin Disease / therapy. Lymph Node Excision
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Neoplasm Recurrence, Local. Prospective Studies. Remission Induction. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12885814.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Ahmad N, Zaidi A, Badar F, Maaz AU, Akram MS: Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia Pac J Clin Oncol; 2010 Mar;6(1):49-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
  • AIM: To analyze the clinical characteristics of B-cell non-Hodgkin's lymphoma (NHL) patients and the therapeutic efficacy of French-American-British Lymphoma Malins de Burkitt 96 and the recent United Kingdom Children's Cancer Study Group B-cell NHL guidelines in the tertiary care hospital of a developing country.
  • Of these 95 had Burkitt's lymphoma, 22 diffuse large B-cell lymphoma and five had B-cell NHL not otherwise specified.
  • A total of 37 had uric acid >10 mg/dl and 55 had a lactate dehydrogenase level >500; 73 had stage III and 31 had stage IV while only four presented at stage I and 14 at stage II.
  • The abdomen was the commonest site of disease.
  • A total of 45 patients died; 28 due to infection, nine due to tumor lysis syndrome and six of uncontrolled disease.
  • All deaths occurred within an average of 35 days from starting treatment.
  • CONCLUSION: Late presentation with advanced disease, poor nutritional status and high risk of exposure to infective agents all contribute to the high mortality in patients treated with intensive protocols in resource-poor countries.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Practice Guidelines as Topic
  • [MeSH-minor] Child. Developing Countries. Female. Humans. Male. Neoplasm Staging. Pakistan. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398038.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


31. Klumb CE, Schramm MT, De Resende LM, Carriço MK, Coelho AM, de Meis E, Ferreira RM, Maia RC, Dobbin Jde A: Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol; 2004 Jul;26(7):462-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
  • PURPOSE: To treat non-Hodgkin's B-cell lymphoma (B-NHL) in children with manageable toxicity-related morbidity and without any decrease in survival.
  • The patients were stratified by risk factors (stage and LDH level) and treated with a BFM 86/90 (Berlin-Frankfurt-Münster)-based protocol with reduction of the methotrexate dose from 5 mg/m to 2 mg/m.
  • Seventy-two percent of the patients had lymphomas classified as Burkitt type, 11% as diffuse large cell lymphoma, and 6% as Burkitt-like lymphoma, and 11% were not classified.
  • The event-free survival rate for all patients was 78% (SE = 0.07): 100% (SE = 0.0) for stage I/II patients and 74% (SE = 0.08) for stage III/IV patients.
  • Six patients suffered initial treatment failure and one patient relapsed, all of whom died.
  • There was only one death from sepsis related to treatment.
  • The results were comparable to those of the BFM 90 study and other contemporary groups and represented an increase in the cure rates in childhood B-NHL in Brazil.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Daunorubicin / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Brazil. Child. Child, Preschool. Female. Humans. Infant. Male. Neoplasm Staging. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15218425.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


32. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P: Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results. Ann Oncol; 2005 Dec;16(12):1936-40
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results.
  • BACKGROUND: Hodgkin's disease (HD) accounts for 7.5% of childhood malignancies in Iran.
  • In order to minimize chemotherapy toxicity and avoid eventual hospitalization and psychological and financial burdens we have applied since 1988, for the first time in Iran, a treatment regimen based on subsequently revised DAL-HD 85-90 and later GPOH-HD 95 protocols.
  • PATIENTS AND METHODS: During the period 1988-2004, 40 children with HD received DAL/GPOH-HD-adapted treatment; 25 males (62.5%) and 15 females (37.5%) (male/female ratio 1.7; age 4-14 years, mean 8.8).
  • Staging was as follows: stage I; seven (17.5%); II, 11 (27.5%); III, 11 (27.5%); and IV, 11 (27.5%).
  • Stage IA and IIA patients (n = 15) received either OPA x2 (vincristine, prednisolone, doxorubicin) or OPPA x2 or OPEA x2 (vincristine, prednisolone, procarbazine and doxorubicin), the latter receiving etoposide instead of procarbazine, and applied to males.
  • Twenty nine patients (72.5%) received radiotherapy (20-25 Gy); four to the involved field (stage I), 25 to the upper mantel (stage II and also III with either residual or mediastinal mass) and three additionally to spleen and para-aortic lymph nodes.
  • Eleven patients received only chemotherapy.
  • Relapse occurred in eight patients (20%); seven stage IV (MC) and one stage IA (LP) with progression to IIIB.
  • Salvage chemotherapy consisted of MOPP/ABVD hybrid; six patients achieved a second sustained remission and three patients died: two due to relapse and progressive disease and the third one in CR, owing to thrombocytopenic hemorrhage and foudroyant pneumonia.
  • Aside from minor acute toxicities, three patients demonstrated azoospermia at the age of 18 years and one of these patients suffered non-Hodgkin lymphoma as a second malignancy.
  • HD occurred as a second malignancy in two patients with acute lymphoblastic leukemia.
  • Both received appropriate treatment and are over 10 years in CR.
  • CONCLUSIONS: The DAL/GPOH-HD-based treatment approach proved to achieve long-term sustained cure even in children with advanced HD disease.
  • The essentially outpatient diagnosis and treatment modus did not compromise the disease outcome, and was well tolerated and accepted by the patients and their parents.
  • The employed drugs are easily available and affordable.
  • This treatment approach is suitable for ambulatory use in developing countries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157620.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Balwierz W, Moryl-Bujakowska A, Depowska T, Klekawka T, Stanuch H, Matysiak M, Sopyło B, Kołakowska-Mrozowska B, Krenke K, Chybicka A, Raś M, Sońta-Jakimczyk D, Moszant A, Wachowiak J, Kaczmarek-Kanold M, Kowalczyk J, Odój T, Balcerska A, Drozyńska E, Wysocki M, Kołtan A, Krawczuk-Rybak M, Stolarska M: [Influence of age on treatment results in children and adolescents with Hodgkin's disease]. Przegl Lek; 2004;61 Suppl 2:40-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of age on treatment results in children and adolescents with Hodgkin's disease].
  • Over the last few years, treatment failures (progression, relapse) in Hodgkin's disease (HD) occurred mainly in elder children treated in the Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG) participating centers.
  • That is why analysis of the influence of age on the treatment outcome in children and adolescents treated with the protocol introduced in 1997 was performed.
  • In years 1997-2001, in 10 centers of PPLLSG, 280 patients (age 2.3-18.8 years) were treated for HD.
  • In all patients MVPP and B-DOPA chemotherapy with or without radiotherapy was introduced.
  • All children with relapse were over 10 years old at the time of diagnosis (range: 10.6-17.1, median 14.6 years); mediastinal tumor mass was present in all of them.
  • Among children over the 10th year of age some features of the disease occurred more frequently: female sex, shorter history of the disease, presence of mediastinal tumor, greater stage of the disease, NS histopathological type of the disease, presence of general signs and ESR over 50 mm, greater tumor burden and higher number of involved lymphatic regions.
  • The aim of the further treatment modifications ought to comprise the need of better treatment outcome, especially in patients over the 10th years of age in which unfavorable prognostic factors are identified. child with relapse) was identified as the border value.
  • Among children over the 10th year of age some features of the disease occurred more frequently: female sex, shorter history of the disease, presence of mediastinal tumor, greater stage of the disease, NS histopathological type of the disease, presence of general signs and ESR over 50 mm, greater tumor burden and higher number of involved lymphatic regions.
  • The aim of the further treatment modifications ought to comprise the need of better treatment outcome, especially in patients over the 10th years of age in which unfavorable prognostic factors are identified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / epidemiology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Age Distribution. Age Factors. Bleomycin / administration & dosage. Chemotherapy, Adjuvant / statistics & numerical data. Child. Child, Preschool. Dacarbazine / administration & dosage. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Doxorubicin / administration & dosage. Female. Humans. Logistic Models. Male. Multicenter Studies as Topic. Poland / epidemiology. Prednisone / administration & dosage. Radiotherapy Dosage. Radiotherapy, Adjuvant / statistics & numerical data. Recurrence. Remission Induction. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686044.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; B-DOPA protocol
  •  go-up   go-down


34. Seidemann K, Tiemann M, Lauterbach I, Mann G, Simonitsch I, Stankewitz K, Schrappe M, Zimmermann M, Niemeyer C, Parwaresch R, Riehm H, Reiter A, NHL Berlin-Frankfurt-Münster Group: Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group. J Clin Oncol; 2003 May 1;21(9):1782-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group.
  • PURPOSE: Primary mediastinal large B-cell lymphoma with sclerosis (PMLBL) is a rare entity of non-Hodgkin's lymphoma (NHL) arising from thymic mature B cells.
  • Optimal treatment strategies remain to be established, especially in pediatric patients.
  • PATIENTS AND METHODS: This study analyzes clinical characteristics and treatment outcome of 30 pediatric patients with PMLBL, diagnosed in multicenter therapy NHL-Berlin-Frankfurt-Münster Group (BFM) trials.
  • Treatment was stratified by stage and serum lactate dehydrogenase (LDH) and consisted of four to six 5-day courses of chemotherapy using steroids, oxazaphosphorine alkylating agents, methotrexate, cytarabine, etoposide, and doxorubicin.
  • With a median observation time of 5 years (range, 1 to 12 years), probability of event-free survival (pEFS) at 5 years was 0.70 (SE, 0.08).
  • Two patients erroneously diagnosed as T-cell NHL received non-B-cell therapy and died from progress of disease.
  • Events in 28 patients receiving B-cell therapy included early progress during therapy (n = 1) and relapse (n = 6).
  • Residual mediastinal masses were present in 23 patients after two courses of therapy and in 15 patients after the end of therapy.
  • Dose-intense chemotherapy including high-dose methotrexate yields a pEFS at 5 years of 0.70 (SE, 0.08).
  • LDH is of prognostic value in pediatric patients with PMLBL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Child. Child, Preschool. Cytarabine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Infant. L-Lactate Dehydrogenase / analysis. Male. Methotrexate / administration & dosage. Prognosis. Sclerosis / etiology. Sclerosis / pathology. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12721255.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; EC 1.1.1.27 / L-Lactate Dehydrogenase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


35. Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A: Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol; 2003 Mar;82(3):160-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
  • To evaluate the clinical benefit of the prophylactic use of urate oxidase in children with non-Hodgkin's lymphoma (NHL), we analyzed the incidence and complications of tumor lysis syndrome (TLS) in children with B-cell acute lymphoblastic leukemia (B-ALL) or stage III/IV Burkitt's lymphoma and a lactate dehydrogenase (LDH) level > or =500 U/l before and after the introduction of a protocol amendment to use urate oxidase for the prophylaxis of TLS.
  • From November 1997 all children with B-ALL or stage III and IV B-NHL and LDH > or =500 U/l should receive urate oxidase prophylactically (period 3).
  • Initial chemotherapy was identical.
  • Altogether, 78 children (4.4%) developed a TLS.
  • Patients with B-ALL had the highest risk to develop a TLS (26.4%) followed by B-ALL/Burkitt's lymphoma and a LDH > or =500 U/l (14.9%).
  • In period 1, 16.1% and 9.2% of the latter children developed a TLS or anuria, respectively, compared to 12.3% and 6.2% in period 3 ( p=NS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Burkitt Lymphoma / drug therapy. Tumor Lysis Syndrome / prevention & control. Urate Oxidase / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12634948.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.7.3.3 / Urate Oxidase
  •  go-up   go-down


36. Yang CP, Hung JJ, Jaing TH, Lin KH, Lin DT, Lu MY, Liang DC, Chen SH, Liu HC, Hsiao CC, Shu SG, Chen JS, Chang TT, Chiou SS, Hsieh YL, Lin MT, Lee MT, Peng CT, Cheng SN, Chen RL, Chen BW, Lin KS: Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin's lymphomas in Taiwan: a report from the Taiwan Pediatric Oncology Group (TPOG). Acta Paediatr Taiwan; 2000 Jul-Aug;41(4):193-204

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin's lymphomas in Taiwan: a report from the Taiwan Pediatric Oncology Group (TPOG)
  • A nation-wide chemotherapeutic trial for childhood non-Hodgkin's lymphoma (NHL) was conducted by the Taiwan Pediatric Oncology Group (TPOG).
  • Four TPOG-NHL92 protocols based on stage and histology were activated in 1992: TPOG-92LD (treatment duration: 8 months) was used for localized (stages I/II) NHL with any histology, 92LB (2 years), 92SNC (5 months), and 92LC (1 year) for advanced (stages III/IV) lymphoblastic (LB), small non-cleaved cell (SNC), and large cell (LC) lymphoma, respectively.
  • Stages I, II, III, and IV (including B-ALL) of the disease comprised 5%, 10%, 43%, and 42% of cases, respectively.
  • There were 176 patients eligible for evaluation of treatment results.
  • As of August 31, 1999, 26 patients relapsed, six died during remission, one patient developed secondary acute myelomonocytic leukemia, and 105 patients remained in continuous remission with a median remission duration of 49 months.
  • The 7-year EFS for stages I/II, III, and IV of the disease was 73%, 68.9%, and 50.3% (P = 0.0212), respectively.
  • We concluded that following the strategy of stratification of therapy, only disease stages had prognostic significance in this study.
  • More efforts are needed to improve our treatment results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Paediatr Taiwan. 2000 Jul-Aug;41(4):175-6 [11021000.001]
  • (PMID = 11021005.001).
  • [ISSN] 1608-8115
  • [Journal-full-title] Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi
  • [ISO-abbreviation] Acta Paediatr Taiwan
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


37. Dharnidharka VR, Douglas VK, Hunger SP, Fennell RS: Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient. Pediatr Transplant; 2004 Feb;8(1):87-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient.
  • Lymphoid malignancies such as post-transplant lymphoproliferative disease (PTLD) are a major complication of solid organ transplantation.
  • Hodgkin's lymphoma (HL) is not part of the typical spectrum of PTLD, but has rarely been reported as a separate complication.
  • A 9-yr-old girl with end-stage autosomal recessive polycystic kidney disease received a cadaveric renal transplant at 1 yr of age.
  • She developed polymorphic PTLD localized to the bone marrow at 6 yr post-transplant.
  • No chemotherapy or anti-B cell antibody was administered.
  • She was treated with standard combination chemotherapy for HL with COPP/ABV.
  • True HL following PTLD has been reported in only three previous cases, with good response to standard chemotherapy in each.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / virology. Immunosuppression / adverse effects. Kidney Transplantation. Lymphoproliferative Disorders / etiology


38. Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB: Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol; 2005 Jan 20;23(3):541-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial.
  • PURPOSE: The Pediatric Oncology Group adopted a histology-based approach to non-Hodgkin's lymphoma and treated patients with advanced large-cell lymphoma on a separate protocol (doxorubicin, vincristine, prednisone, 6-mercaptopurin, and methotrexate; APO regimen).
  • In this study, we assessed the effects of an intense antimetabolite therapy alternating with APO on overall survival (OS) and event-free survival (EFS) and looked into biologic correlates.
  • PATIENTS AND METHODS: From December 1994 to April 2000, we enrolled 180 eligible pediatric patients with stage III/IV large-cell lymphoma (LCL); 90 patients were randomly assigned to the intermediate-dose methotrexate (IDM) and high-dose cytarabine (HiDAC) arm, 85 patients to the APO arm, and five patients directly to the APO arm by study design due to CNS involvement.
  • Planned therapy duration was 12 months.
  • RESULTS: The 4-year EFS for all patients was 67.4% (SE, 4.2%), and OS was 80.1% (SE, 3.6%) without any significant difference between the two arms.
  • The 4-year EFS and OS were 71.8% (SE, 6.1%) and 88.1% (SE, 4.4%), respectively, for patients with anaplastic large-cell lymphoma, and 63.8% (SE, 10.3%) and 70.3% (SE, 9.0%), respectively, for patients with diffuse large B-cell lymphoma.
  • Only 11 patients required radiation (due to unresponsive bulky disease or CNS involvement).
  • CONCLUSION: The efficacy of incorporating IDM/HiDAC in the treatment plan of pediatric and adolescent patients with advanced-stage LCL was inconclusive as to its effect on EFS, regardless of the lymphoma phenotype.
  • It cannot be excluded that with a higher number of patients, one treatment could prove superior and future studies will build on these data.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Staging
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Adult. Age Factors. Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Infant. Infusions, Intravenous. Injections, Spinal. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15659500.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; APO combination
  •  go-up   go-down


39. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol; 2006 Jan 20;24(3):491-9
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.
  • PURPOSE: In the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Munster (NHL-BFM) 95 trial, we tested, against the historical control of the combined trials NHL-BFM90 and NHL-BFM86, whether prophylactic cranial radiotherapy (PCRT) can be omitted for CNS-negative patients with stage III or IV lymphoblastic lymphoma (LBL) with sufficient early response.
  • PATIENTS AND METHODS: Apart from the removal of PCRT in NHL-BFM95, the chemotherapy of the three trials was identical except for the amount of l-asparaginase and daunorubicin during induction.
  • The therapy in NHL-BFM95 was accepted to be noninferior when compared with trials NHL-BFM90/86 if the lower limit of the one-sided 95% CI for the difference in the 2-year probability of event-free-survival (pEFS) between target patients of NHL-BFM95 and the historical controls of NHL-BFM90/86 did not exceed -14%.
  • The target patient group consisted of stage III and IV patients who were CNS negative and responded well to induction therapy.
  • For the target group, the pEFS rates at 2 and 5 years were 86% +/- 3% and 82% +/- 3%, respectively, in NHL-BFM95 (median follow-up time, 5.1 years; range, 2.1 to 9.1 years) compared with 91% +/- 2% and 88% +/- 3%, respectively in NHL-BFM90/86 (median follow-up time, 10.7 years; range, 5 to 15.4 years).
  • Five-year disease-free-survival rate was 88% +/- 3% in NHL-BFM95 compared with 91% +/- 2% in NHL-BFM90/86.
  • CONCLUSION: For CNS-negative patients with stage III or IV LBL and sufficient response to induction therapy, treatment without PCRT may be noninferior to treatment including PCRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / prevention & control. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Asparaginase / administration & dosage. Child. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16421426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


40. Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM: Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol; 2009 Mar 20;27(9):1456-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
  • PURPOSE: The Children's Oncology Group conducted this phase II study to assess the efficacy and toxicity of gemcitabine and vinorelbine (GV) in pediatric patients with heavily pretreated relapsed/refractory Hodgkin's disease.
  • METHODS: GV was given on days 1 and 8 of each 21-day treatment cycle: vinorelbine 25 mg/m(2)/dose administered via intravenous (IV) push before gemcitabine 1,000 mg/m(2)/dose IV over 100 minutes.
  • A two-stage minimax rule was used to test the null hypothesis that the response rate is <or= 40% against an alternative hypothesis of a response rate more than 65%.
  • All patients had received at least two prior chemotherapy regimens, and 17 patients had undergone prior autologous stem-cell transplantation.
  • Hematologic toxicity was predominant in all treatment cycles.
  • Pericardial and pleural effusions developed in one patient after cycles 4 and 5 of GV, consistent with gemcitabine-induced radiation recall.
  • CONCLUSION: GV is an effective and well-tolerated reinduction regimen for children with relapsed or refractory Hodgkin's disease.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000 Apr;11(4):495-6 [10847474.001]
  • [Cites] Intern Med J. 2007 Nov;37(11):760-6 [17542998.001]
  • [Cites] Anticancer Drugs. 1999 Jul;10(6):525-31 [10885899.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2529-36 [10893283.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):573-6 [10944594.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):763-8 [10951338.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):707-14 [10952772.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):873-5 [10997817.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):993-8 [11038036.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):277-84 [11165408.001]
  • [Cites] Oncologist. 2001;6 Suppl 1:16-9 [11182000.001]
  • [Cites] Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):15-7 [11252883.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):583-90 [11290433.001]
  • [Cites] Invest New Drugs. 2001;19(1):101-4 [11291828.001]
  • [Cites] Oncologist. 2001;6(2):153-61 [11306727.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):830-5 [11550154.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Aug;48(2):151-9 [11561781.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):37-41 [11773151.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Jan;29(1):107-9 [11816464.001]
  • [Cites] Invest New Drugs. 2002 Feb;20(1):73-82 [12003196.001]
  • [Cites] Breast J. 2002 May-Jun;8(3):171-6 [12047474.001]
  • [Cites] Clin Breast Cancer. 2002 May;3 Suppl 1:34-8 [12057044.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):340-53 [12124835.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1862-7 [12453853.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Apr;30(4):515-7 [12722684.001]
  • [Cites] Clin Breast Cancer. 2003 Apr;4(1):46-50 [12744758.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):421-2 [14599876.001]
  • [Cites] Cancer. 2004 May 1;100(9):1793-9 [15112258.001]
  • [Cites] Pediatr Hematol Oncol. 2004 Mar;21(2):107-13 [15160509.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2348-56 [15197195.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):556-61 [3559649.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1463-9 [10526274.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):405-11 [10637256.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):557-62 [10649247.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Lung Cancer. 2000 Jan;27(1):47-53 [10672783.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;27(4):258-62 [1998982.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):406-13 [1740680.001]
  • [Cites] Ann Oncol. 1994 Nov;5(9):817-20 [7531487.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10 [7481842.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):409-14 [8882953.001]
  • [Cites] Invest New Drugs. 1997;15(2):115-21 [9220290.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):191-201 [9625429.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):195-208 [9720729.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1003-8 [9818075.001]
  • [Cites] Hematol Oncol. 1998 Sep;16(3):101-5 [10235068.001]
  • [Cites] Anticancer Drugs. 1999 Aug;10(7):625-31 [10507311.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4532-40 [15542804.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):141-5 [16007883.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1473-8 [15870180.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1313-20 [16109609.001]
  • [Cites] Anticancer Drugs. 2006 Jan;17(1):107-11 [16317298.001]
  • [Cites] JOP. 2006;7(3):306-10 [16685112.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Strahlenther Onkol. 2007 Apr;183(4):215-7 [17406804.001]
  • [Cites] Chest. 2000 Jun;117(6):1583-9 [10858387.001]
  • (PMID = 19224841.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA98543
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC2668553
  •  go-up   go-down


41. Roh JL, Huh J, Moon HN: Lymphomas of the head and neck in the pediatric population. Int J Pediatr Otorhinolaryngol; 2007 Sep;71(9):1471-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomas of the head and neck in the pediatric population.
  • OBJECTIVE: Little is known about the incidence and survival outcomes of pediatric patients with head and neck (HN) lymphomas in Asian populations.
  • This study sought to identify the incidence of HN involvement of pediatric lymphomas and to identify factors prognostic of patient survival.
  • METHODS: We reviewed the medical records of all children aged 0-14 years with previously untreated lymphomas of HN region and compared patient clinicopathologic characteristics and final outcomes in patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
  • RESULTS: Of 106 eligible lymphoma patients, 45 (42.5%; 31 boys and 14 girls) showed HN involvement.
  • Overall, NHL (n=37) showed more unusual and aggressive presentations than did HD (n=8) in the head and neck region.
  • Involvement of extralymphatic head and neck sites was found in 15 of 37 NHL patients (40.5%) but not in any HD patients (p=0.027).
  • Five-year disease-free survival (DFS) of all HN lymphoma patients was 76.0%.
  • On multivariate analysis, advanced stage and absence of complete remission following 3 cycles of chemotherapy were poor prognostic indicators of patient survival (p<0.05).
  • CONCLUSIONS: The incidence of HN involvement in pediatric lymphomas was 42.5% in the studied population.
  • Stage of the lesion and early response to chemotherapy were independent factors prognostic of patient survival.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / pathology. Lymphoma / mortality. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease Progression. Female. Hodgkin Disease / mortality. Hodgkin Disease / pathology. Hodgkin Disease / radiotherapy. Humans. Infant. Infant, Newborn. Lymphatic Diseases / epidemiology. Male. Neck. Prevalence. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624446.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


42. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, Schirg E, Henze G, Schellong G, Gadner H, Riehm H: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood; 2000 Jan 15;95(2):416-21
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.
  • The purpose of our study was to investigate the efficacy of an acute lymphoblastic leukemia (ALL)-type treatment with moderate-dose, prophylactic cranial irradiation and without local radiotherapy for childhood T-cell lymphoblastic lymphoma (T-LBL).
  • From April 1990 to March 1995, 105 evaluable patients, 1.1 to 16.4 years of age, with T-LBL were enrolled in study NHL-BFM 90 (non-Hodgkin's lymphoma-Berlin-Frankfurt-Munster 90).
  • They received an 8-drug induction over 9 weeks followed by an 8-week consolidation including methotrexate (MTX) 5 g/m(2) x 4.
  • Patients with stage I (n = 2) and II (n = 2) continued with maintenance therapy (6-mercaptopurine daily and MTX weekly, both orally) until a total therapy duration of 24 months.
  • Patients with stage III (n = 82) and IV (n = 19) received an 8-drug intensification over 7 weeks and cranial radiotherapy (12 Gy for prophylaxis) after consolidation, followed by maintenance.
  • Patients received intensified chemotherapy if tumor regression on day 33 of induction was less than 70% or when vital residual tumor was present after the complete induction phase.
  • Two patients received intensified therapy due to less than 70% tumor regression on day 33.
  • We conclude that, with intensive ALL-type chemotherapy including moderate cumulative doses of anthracyclines 240 mg/m(2) and cyclophosphamide (3 g/m(2)) and moderate-dose prophylactic cranial irradiation but no local radiotherapy, an event-free survival rate of 90% can be achieved in childhood T-LBL. (Blood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Methotrexate / administration & dosage. Neoplasm Staging. Probability. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10627444.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


43. Hasanbegović E, Sabanović S: The results of Hodgkin lymphoma treatment in children in the period 1997-2006. Bosn J Basic Med Sci; 2008 Feb;8(1):72-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of Hodgkin lymphoma treatment in children in the period 1997-2006.
  • In this paper we present the study of chemotherapy and radiotherapy treatment success in children suffering from Hodgkin's disease (HD) that were treated at Hematology-oncology Department of Pediatric Clinic in Sarajevo.
  • In retrospective study we followed all patients with HD aged 0-15 who were diagnosed with and treated for HD at Pediatric Clinic in Sarajevo over the last 10 years (1st of January 1997 - 31st of December 2006).
  • Until 2000 we used combination of chemotherapy and radiotherapy according to UKCCSG HD 9201 treatment protocol, and after the year 2000 protocol UKCCSG HD 2000 (ChlVPP / ABVD) was applied.
  • In 10 patients (30,3 %) we found II A stage of HD, in 4 (12,1 %) II B stage of HD, in 6 children (18,8 %) stage III A, in 4 children (12,1 %) stage III B, in 4 children (12,1 %) stage IV A and in 5 (15,1 %) stage IV B.
  • In 7 patients (21,2 %) relapse occurred, which demanded more aggressive chemotherapeutic treatment and radiotherapy too; while for 4 patients (12,1 %) in combination with bone marrow transplantation.
  • There are 30 children (91,0 %) who are alive and in either 1st or 2nd remission phase of HD.
  • Although many patients (58,1%) were diagnosed in an advanced stage of illness (III and IV) the results of HD therapy at Pediatric Clinic in Sarajevo are comparable to those in other European centers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Bone Marrow Transplantation. Bosnia and Herzegovina. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Infant, Newborn. Male. Remission Induction / methods. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1992 Sep;3 Suppl 4:77-81 [1450085.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):139-44 [16642484.001]
  • [Cites] Br J Haematol. 2003 Sep;122(5):718-27 [12930382.001]
  • [Cites] Eur J Cancer. 1998 Mar;34(4):523-8 [9713303.001]
  • [Cites] Med Pediatr Oncol. 2003 Jan;40(1):66-9 [12426693.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S115-9 [9926249.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):468-77 [11872338.001]
  • [Cites] Ann Oncol. 1996;7 Suppl 4:73-8 [8836414.001]
  • (PMID = 18318676.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


44. Halperin EC, Laurie F, Fitzgerald TJ: An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a Quality Assurance Review Center-Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys; 2002 Jul 15;53(4):1001-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a Quality Assurance Review Center-Pediatric Oncology Group study.
  • PURPOSE: The Pediatric Oncology Group Protocol 9404 was a prospective clinical trial of two forms of chemotherapy in childhood T-cell acute lymphoblastic leukemia and advanced stage T-cell lymphoblastic non-Hodgkin's lymphoma.
  • The protocol called for prophylactic C1 whole brain external beam irradiation, 18 Gy in 2 Gy/fraction for 9 fractions.
  • Treatment volumes were scored as a minor deviation if the margins were less than specified or the fields were excessively large.
  • When the treating physician submitted a treatment plan and simulator film at the initiation of therapy to the Quality Assurance Review Center (QARC), a rapid turn-around review of the plan and suggestions for improvement was provided.
  • At the end of therapy, all simulator and port films were reviewed at the QARC.
  • The frequency of major deviations fell over time (1996-1997, 15.5% vs. 1998-2001, 4.7%, p < 0.001).
  • A trend (p < 0.09) was noted, however, for major deviations to decrease as a function of institutional experience, as well as over time (p < 0.001), supporting the validity of the hypothesis that pediatric clinical experience matters in QA for C1 whole brain leukemia radiotherapy.
  • [MeSH-major] Brain / radiation effects. Clinical Trials as Topic / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12095569.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA15525-29; United States / NCI NIH HHS / CA / CA29511
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


45. Patte C, Sakiroglu O, Sommelet D: European experience in the treatment of hyperuricemia. Semin Hematol; 2001 Oct;38(4 Suppl 10):9-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European experience in the treatment of hyperuricemia.
  • The nonrecombinant form of urate oxidase has been routinely used in France since 1975 as standard practice in the initial management of non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL), and for prevention of tumor lysis syndrome (TLS).
  • A retrospective study was performed to evaluate the frequency of metabolic complications and dialysis in 410 patients with B-cell stage III and IV NHL and L-3 ALL treated in France according to the LMB89 protocol, and to compare these results to those of other series of patients treated without urate oxidase.
  • Of the 57 patients treated at Institut Gustave-Roussy, only five had metabolic complications occurring in the first cycle of chemotherapy.
  • A recombinant form of urate oxidase (rasburicase) was therefore developed.
  • European clinical development results indicate that this agent produces a sharp and consistent decrease in uric acid levels in patients undergoing cytoreductive therapy.
  • Studies have demonstrated the efficacy of urate oxidase in lowering uric acid levels, preventing hyperuricemia after the initiation of cytoreductive therapy, and preserving renal function in patients with B-cell advanced stage NHL and ALL.
  • [MeSH-minor] Adolescent. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / toxicity. Child. Child, Preschool. Clinical Trials as Topic. Europe. Female. Humans. Leukemia, B-Cell / blood. Leukemia, B-Cell / complications. Leukemia, B-Cell / drug therapy. Lymphoma, B-Cell / blood. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Male. Retrospective Studies. Treatment Outcome. Tumor Lysis Syndrome / drug therapy. Tumor Lysis Syndrome / etiology. Tumor Lysis Syndrome / prevention & control. Urate Oxidase / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11694946.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 268B43MJ25 / Uric Acid; EC 1.7.3.3 / Urate Oxidase
  •  go-up   go-down


46. Snyder RL: Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use. Am J Health Syst Pharm; 2007 Jun 1;64(11):1163-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The successful resumption of high-dose methotrexate in a 13-year-old boy with recurrent anaplastic large-cell lymphoma (ALCL) who suffered renal dysfunction after a 24-hour infusion of high-dose methotrexate and required treatment with carboxypeptidase G(2) (CPDG(2) ) is described.
  • SUMMARY: A 13-year-old boy who had been diagnosed in 2001 with stage I ALCL was admitted to the hospital in February 2005 after he developed a smaller left axillary mass in the area of his original mass.
  • Recurrent ALCL was diagnosed, and treatments were initiated based on branch K3 of the protocol published in the non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster (NHL-BFM) trial 90.
  • In the NHL-BFM 90 protocol, all AA and BB courses include high-dose methotrexate therapy, which consists of aggressive alkalinized hydration, methotrexate 5 g/m(2) given as an i.v. infusion over 24 hours, and leucovorin rescue.
  • Because the patient's elimination of methotrexate remained slow and his serum creatinine level remained above normal limits, CPDG(2) was obtained for the treatment of methotrexate toxicity.
  • He is currently in remission on maintenance therapy.
  • The resultant delayed methotrexate clearance required the standard therapies as well as use of investigational CPDG(2).
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Renal Insufficiency / drug therapy. gamma-Glutamyl Hydrolase / therapeutic use
  • [MeSH-minor] Adolescent. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local. Retreatment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519458.001).
  • [ISSN] 1079-2082
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 3.4.19.9 / gamma-Glutamyl Hydrolase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement